Gender Differences in Insomnia: Why Women Are Twice as Likely to Suffer and What the Science Shows

Across pretty much every culture, country, and research approach that has bothered to measure it carefully, the pattern shows up again and again: women are about twice as likely as men to experience insomnia.

That 2:1 split is one of those rare findings in sleep research that hardly wobbles, no matter who’s asking the question or where they’re asking it.

And it’s not just a story about women being more willing to say, “I’m not sleeping well.” When researchers skip the surveys and go straight to polysomnography, the lab-based sleep test that tracks sleep stages and fragmentation, the gap still holds.

These studies often show shorter sleep and more disrupted sleep in women compared with men. In other words, this isn’t merely a reporting difference. It points to something physiological, not just observational.

Once you start taking that seriously, the next question changes shape. It stops being “Why do women complain about sleep more?” and becomes “What is it about the body and the life course that makes sleep more vulnerable at certain times?”

And that question matters, because knowing why it happens, and when it tends to spike across a woman’s life, can change how you think about both prevention and treatment.

What follows is the full map: the hormonal scaffolding that affects sleep, the reproductive life stages where insomnia risk tends to flare up, and the social and structural pressures that can turn a biological vulnerability into a chronic problem.

The 2:1 Ratio and What It Actually Means

The gender gap in insomnia prevalence appears in the data from every country that has collected it. Approximately 40 percent of women will experience significant insomnia at some point in adulthood, compared to about 30 percent of men.

The gap widens at hormonal transition points and narrows in older age as the hormonal fluctuations of the reproductive years resolve. This matters for treatment because insomnia in women often has causes that are invisible in standard clinical assessment.

A woman presenting with insomnia at 48 who is experiencing perimenopausal symptoms and interrupted sleep from hot flashes has a different primary problem than a man of the same age with a stressful job. The same generic insomnia advice applied to both of them will produce different results.

The Hormonal Architecture of Female Sleep

Two hormones sit at the centre of the gender sleep gap: progesterone and estrogen. Both directly modulate the neurological systems that control sleep onset, sleep maintenance, and sleep architecture.

Progesterone: The Sleep-Promoting Hormone

Progesterone and its primary metabolite, allopregnanolone, are positive modulators of GABA-A receptors. This is the same receptor system that benzodiazepines and Z-drugs pharmacologically enhance. When progesterone is present in adequate levels, it produces GABAergic effects that support sleep onset and maintenance.

The sleep disruption comes from withdrawal. Progesterone rises after ovulation (day 14 of the menstrual cycle) through the luteal phase, then falls sharply in the days before menstruation.

When it falls, the GABA-A support it was providing is abruptly withdrawn. This produces the premenstrual insomnia that many women experience regularly but rarely attribute to a hormonal mechanism.

Estrogen: The Circadian and Architecture Modulator

Estrogen’s sleep functions are multiple and distinct. It modulates serotonin and noradrenaline — neurotransmitters that regulate mood and sleep. It helps maintain the stable core body temperature required for good sleep. It influences REM sleep density. And it plays a role in circadian clock regulation.

The critical point about estrogen and sleep is that fluctuation is more disruptive than level. A stable low estrogen level, as in the postmenopause, is often less disruptive to sleep than the rapid, unpredictable fluctuations of the menopausal transition.

This is why sleep often improves once the perimenopause resolves, even though estrogen levels remain low. Stability is what sleep requires.

Sleep Across the Female Reproductive Lifespan

The Menstrual Cycle

The follicular phase (days 1 to 14) is when sleep is typically most stable for cycling women. Progesterone and estrogen are lower and more consistent. Sleep architecture is as close to baseline as it gets.

The luteal phase (days 15 to 28) begins well — rising progesterone initially supports sleep. But as the cycle approaches its end, progesterone withdrawal in days 25 to 28 produces the premenstrual insomnia that 70 percent of women with PMS report as a symptom.

For women with PMDD (premenstrual dysphoric disorder), the sleep disruption is severe enough to produce significant functional impairment, and requires specific clinical attention rather than generic sleep advice.

Pregnancy by Trimester

The first trimester brings elevated progesterone, which produces daytime somnolence alongside disrupted nighttime sleep architecture. Nausea and urinary frequency cause nighttime awakenings that worsen throughout weeks six to ten.

Anxiety about the pregnancy is a significant cognitive arousal driver that is often underaddressed because clinicians focus on physical symptoms.

The second trimester is typically the best sleep period of pregnancy. Hormonal levels stabilise somewhat, nausea often reduces, and physical size hasn’t yet created the positional and comfort challenges of later pregnancy. Sleep architecture studies still show reduced slow-wave sleep relative to pre-pregnancy baseline, but subjective sleep quality usually improves.

The third trimester is where the data is most striking. Seventy-six percent of pregnant women report insomnia by the third trimester.

The causes compound: physical discomfort from uterine size; restricted sleep positions (left lateral decubitus is recommended); backache; urinary frequency at two to three voids per night; foetal movement at times that don’t align with maternal sleep timing; and anticipatory anxiety about labour, delivery, and new parenthood.

Restless legs syndrome prevalence increases dramatically in pregnancy, peaking in the third trimester. The mechanism is the iron and folate demands of pregnancy depleting stores available for CNS dopamine synthesis.

If you have RLS in pregnancy, serum ferritin is the relevant test, and iron supplementation with appropriate medical guidance often produces significant symptom improvement.

Perimenopause and Menopause: The Peak Risk Period

Insomnia affects 40 to 60 percent of perimenopausal and postmenopausal women, making this the highest-risk sleep period across the entire female reproductive lifespan.

The peak disruption tends to occur during perimenopause rather than the established postmenopause, which is consistent with the fluctuation-over-level principle: erratic hormone swings are more disruptive to sleep than a stable new hormonal baseline.

The Vasomotor Symptom Pathway

Hot flashes during sleep are the most direct mechanism. The hypothalamic thermoregulatory disruption produces sudden core temperature elevation, which is one of the most powerful physiological arousal triggers available. Sleep fragmented by hot flash events accumulates significant sleep debt over months.

Women with menopausal insomnia often report disturbed sleep on nights without hot flash events, which suggests additional mechanisms beyond the vasomotor pathway. Estrogen decline removes its serotonin-modulating and thermoregulatory functions simultaneously.

Progesterone decline removes the GABA-A support. The combined withdrawal of both sleep-promoting hormonal influences during a single transition period is, in physiological terms, a significant sleep disruption event.

Treatment for Menopausal Insomnia

Hormone replacement therapy has the strongest evidence for treating both vasomotor symptoms and the sleep disruption they cause. The improvement in sleep quality with HRT is significant and well-documented, particularly when vasomotor symptoms are the primary driver of the insomnia.

CBT-I is effective for the conditioned insomnia component that develops secondary to years of hot-flash-disrupted sleep. By the time a woman reaches a sleep specialist with perimenopausal insomnia, she often has both vasomotor-driven disruption and conditioned arousal — the brain has learned to expect disruption and maintains wakefulness even on nights when the hot flashes don’t appear.

Both components need treatment.

Beyond Hormones: The Social and Structural Factors

Hormones explain a significant portion of the gender sleep gap. They don’t explain all of it.

Women’s greater responsibility for childcare, household management, and caregiving for elderly relatives creates a specific bedtime cognitive pattern. The mental processing of logistics, which child has which commitment tomorrow, what’s needed for a school event, what a parent’s next appointment requires — is a form of cognitive hyperarousal with a structural cause.

It’s not a personality tendency. It’s a reflection of who carries the cognitive load in most households.

The Rumination Difference

Women show greater pre-sleep rumination than men in research comparing the two. The content is specifically about relationship and social concerns rather than task or achievement concerns.

This pattern compounds hormonal vulnerability with an independent cognitive arousal pathway. It’s not anxiety disorder (though anxiety, which is more common in women, amplifies it) — it’s a characteristic of how social cognition intersects with the pre-sleep window.

Anxiety Rates and Sleep

Women have higher rates of anxiety disorders than men across most diagnostic categories. Anxiety and insomnia have a bidirectional relationship: anxiety causes insomnia, and insomnia amplifies anxiety.

The higher baseline anxiety rate in women produces a compounding effect with the hormonal vulnerabilities described above.

Treatment Implications: What Works When

Menstrual-phase insomnia specifically benefits from cognitive techniques targeting anticipatory anxiety about sleep in the premenstrual week. Scheduling lower-demand activities in the week before menstruation reduces the stress load at the most vulnerable point.

Women using hormonal contraceptives can discuss formulations with a prescriber — some oral contraceptive formulations reduce the hormonal fluctuations that drive premenstrual sleep disruption.

Pregnancy insomnia calls for CBT-I adapted for pregnancy (standard sleep restriction is modified to protect adequate sleep for fetal development), physical comfort interventions (a pregnancy pillow that supports lateral sleeping significantly reduces nighttime repositioning), and assessment for RLS through serum ferritin and folate levels.

Menopausal insomnia benefits from the combination of HRT (for women for whom it’s appropriate and desired) and CBT-I for the conditioned component. Neither alone addresses both mechanisms.

The Under-Referral Problem

Women’s insomnia at hormonal transition points is frequently dismissed in clinical encounters as expected or normal and managed with sleep medication rather than offered CBT-I or appropriate hormonal assessment. Both of those responses are inadequate.

Insomnia is not an expected or untreatable feature of the premenstrual period, pregnancy, or the menopause transition. Each stage has effective, evidence-based interventions that go well beyond “try to sleep better.”

Healthcare visits during hormonal transitions are natural opportunities to screen for sleep problems and offer the right treatment rather than management with hypnotics.

If you’re experiencing insomnia that follows a hormonal pattern, naming that pattern explicitly with your healthcare provider is the most useful thing you can do. It changes what you’re offered.